Current Financial Status of the Yellow Rose Foundation
The Yellow Rose Foundation was formed September 30th, 2004 and began under the management of Okabena Advisors, a Minneapolis based investment firm that specializes in managing investments for tax-exempt entities. We have distributed over two and one half year's worth of asset valuation to three separate organizations while continuing to grow the asset base of the foundation. As of December 2007, our base has grown over 31% with an average annual rate of return on our investments of 10.4%.
"The Yellow Rose Foundation's generous support allows JDRF to fund important human clinical trials and other valuable initiatives that bring us closer to the cure each and every day. Without donors such as the YRF, JDRF would not be able to be the single largest independent funder of diabetes in the world. We are forever grateful for their support."
Vicki Weiland
Executive Director, Greater Bay Area Chapter
Juvenile Diabetes Research Foundation
Financial and Distribution Goals of the Yellow Rose Foundation: 2008 and Beyond
The primary goal of the Yellow Rose Foundation is simple: continue to meet our mission. However, to do this effectively, we must raise enough money to distribute larger contributions to our chosen beneficiaries while maintaining the IRS 501(c)(3) tax-exempt-status criteria under which we are governed. The goal for the capital campaign beginning in 2008 is to raise One Million dollars. If the Yellow Rose Foundation can raise $1 million by year's end, it would have a significantly positive impact on the lives of those living with type 1 diabetes.
Current Financial Status of the Yellow Rose Foundation
However, to do this effectively, we must raise enough money to distribute larger contributions to our chosen beneficiaries while maintaining the IRS 501(c)(3) tax-exempt-status criteria under which we are governed. The goal for the capital campaign beginning in 2008 is to raise One Million dollars. If the Yellow Rose Foundation can raise $1 million by year's end, it would have a significantly positive impact on the lives of those living with type 1 diabetes.